SCHEMBL13797487

SCHEMBL13797487

CC(C)S(=O)(=O)c1ccc(F)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.44
PSEN1 P49768 4/20 0.44
PSEN2 P49810 4/20 0.44
APH1B Q8WW43 4/20 0.44
NCSTN Q92542 4/20 0.44
APH1A Q96BI3 4/20 0.44
PSENEN Q9NZ42 4/20 0.44
TRPV4 Q9HBA0 1/20 0.43
ALK Q9UM73 3/20 0.39
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.37
BRD4 O60885 3/20 0.37
CNR2 P34972 1/20 0.37
CCR2 P41597 1/20 0.37
MCL1 Q07820 1/20 0.37
PTGS2 P35354 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13797489 0.81 TRPV4 (0.48) AKR1B1PSEN1PSEN2APH1BNCSTN
SCHEMBL9963191 0.81 POLB (0.45) AKR1B1PSEN1PSEN2APH1BNCSTN
SCHEMBL17069239 0.79 TSHR (0.45) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL644001 0.79 CCR2 (0.50) AKR1B1TRPV4BRD4CNR2CCR2
SCHEMBL20085640 0.78 NPC1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2413486 0.78 HSD11B1 (0.44) TRPV4ALDH1A1PKMCCR2CA12
SCHEMBL17069302 0.77 PDE2A (0.50) TRPV4ALDH1A1CNR2MCL1
SCHEMBL9963189 0.77 PSEN1 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL68990 0.76 TRPV4 (0.58) AKR1B1PSEN1PSEN2APH1BNCSTN
SCHEMBL29651884 0.76 TRPV4 (0.58) AKR1B1PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550458-B2 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-7550458-B2 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-20070088029-A1 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY 2007-04-19 US disclosed
US-20070088029-A1 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY 2007-04-19 US disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 AKR1B1 727/4885PSEN1 4835/4885PSEN2 4857/4885
US-20070088029-A1 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function VDR, ESRRB, NR5A1 AKR1B1 385/4885PSEN1 4113/4885PSEN2 3916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.